AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals

Drugmaker Astrazeneca said on Friday that it has expanded its weight‑management pipeline after striking a strategic collaboration with CSPC Pharmaceuticals to develop a series of next‑generation obesity and type‑2 diabetes therapies.

Under the deal, AstraZeneca will gain exclusive global rights outside China to CSPC's monthly injectable portfolio, including its long‑acting GLP1R/GIPR agonist moving into Phase I SYH2082, alongside three preclinical assets targeting a range of weight‑related conditions.

The pair will initially advance four programmes using CSPC's AI‑driven peptide discovery platform and its once‑monthly LiquidGel dosing technology. The agreement includes eight programmes, including a clinical-ready asset.

Astrazeneca added that for access to eight programmes, as well as the advanced AI molecular design capabilities and its proprietary LiquidGel once-monthly dosing platform technology, it will make an upfront payment of $1.2bn to CSPC, which was also eligible to receive development and regulatory milestones of up to $3.5bn across all programmes. CSPC will also be eligible for further commercialisation and sales milestones plus tiered royalties.

Astrazeneca said transaction was expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory clearances.

Sharon Barr, Astrazeneca's executive vice president, said: "This strategic collaboration advances our weight management portfolio by delivering novel assets which complement our existing programmes. It will provide access to CSPC's proprietary AI-enabled peptide capabilities and platform technology, which have the potential to transform the treatment of obesity, helping to address adherence and convenience as key barriers to long-term therapeutic success."

Reporting by Iain Gilbert at Sharecast.com